This study explored fluid prescribing practices in intensive care – providing a picture of how fluid resuscitation is being managed internationally. They compared their data from 2014 with those of their previous study in 2007; they found that more crystalloids were being prescribed, particularly buffered salt solutions, while there were less colloids being given overall – semi-synthetic colloids had seen a large decrease, while albumin had seen a relative increase.
Fluid resuscitation is a common intervention in the intensive care unit (ICU) – with around a third of inpatients receiving intravenous fluid resuscitation each day. The authors of the current study conducted an investigation in 2007 to establish the fluid prescribing pattern of 391 ICUs across 25 countries. At that time, hydroxyethyl starch (HES) and ‘normal’ 0.9% saline solution were the most commonly administered colloid and crystalloid solutions respectively. Since that study, evidence has emerged demonstrating an increased risk of adverse events associated with some fluid types. The authors aimed to repeat their study and to contrast practice in 2014 with 2007 to determine what impact the pivotal evidence had generated.
The study followed a cross-sectional, prospective design; the participating departments were contacted with 10 potential dates. On their chosen date, there was a 24-hour period of data collection. Where there was a trend comparison between 2007 and 2014, only those departments participating in both studies were included. Patients over 16 years old who had at least one episode of fluid resuscitation were included; fluid resuscitation was classed as any bolus of fluid, any dose of colloid, or any infusion of crystalloid that was faster than 5 ml/kg/hour. Patient data were collected, as were data on which fluids were administered.
Participating departments included 426 ICUs from 27 countries worldwide. There were 6707 patients covered in that 24-hour period, during which 1456 received resuscitation fluid. There were a total of 2716 resuscitation events.
This saw significant geographical variation; crystalloid administration ranged from 50.8% to 95.4%, while colloid varied from 6.3% to 60.5%. The most widely used crystalloid fluids were buffered salt solutions, (58.0%; 1280/2208 crystalloid resuscitation events) followed by saline (40.6%; 897/2208 crystalloid resuscitation events).
When those units featuring in both 2007 and 2014 were reviewed, it was noted that the number receiving IV fluid resuscitation was similar, while patient characteristics were also similar. The proportion of patients receiving crystalloid increased significantly (45.5% in 2007, 74.3% in 2014; OR=2.98; 95% CI 2.02–4.40; p<0.001), and the overall number of episodes in which crystalloids were administered was higher in 2014 (42.7% in 2007, 72.3% in 2014; OR=3.75; 95% CI 2.95–4.77; p<0.001). The use of colloids also declined, the proportion of patients receiving colloid dropping from 74.0% in 2007 to 30.9% in 2014 (OR=0.27; 95% CI 0.22–0.35; p<0.001). The use of albumin as a proportion of administered colloid increased significantly (OR 8.86; 95% CI 5.87–13.70; p<0.001), while HES decreased significantly (OR=0.16; 95% CI 0.10–0.25; p<0.001). The biggest increase as a proportion of prescribed crystalloid was buffered salt solutions (OR=3.26; 95% CI 2.35–4.52; p<0.001), while saline use decreased significantly (OR=0.33; 95% CI 0.24–0.46; p<0.001).
The findings are consistent with the current literature – showing an increased use of buffered salt solutions, and crystalloid in general. Benefit from buffered salt solutions has largely been demonstrated through observational studies, while a randomised trial comparing buffered salt solutions with saline did not show any benefit relating to acute kidney injury, requirement for renal replacement therapy or in-hospital mortality – the study did only look at elective surgical patients admitted to ICU however. The decrease in use of semi-synthetic colloids is likely to be multifactorial, with the newer evidence base and pivotal randomised trials driving changes to licensing of these products. This has led to albumin becoming the predominant colloid – likely to be due to reduced HES usage, alongside evidence suggesting a benefit of albumin in severe sepsis. The authors mitigated selection bias for this study by only contrasting data from the same ICUs in 2014 as had provided data in 2007, and they prespecified the statistical analysis to avoid confounders. They did not account for availability of fluids, and some countries were under- or over-represented in the analysis.
This study provides a snapshot of changing practice, demonstrating the influence that newer evidence has had on the landscape of fluid prescription in intensive care.
Catch-up on the debate surrounding hydroxyethyl starch use as we take you on an interactive journey through its changing fortunes. Do you think current restrictions will be enough to change clinical practice?
This position paper from the Italian Association for the Study of the Liver (AISF) and the Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) reviews the evidence for the use of albumin in several settings related to liver cirrhosis.
This paper presents a meta-analysis to determine the impact of resuscitation with albumin on the morbidity and mortality of adult burn patients.
This meta-analysis examines whether the dosing of albumin affects outcomes in type 1 hepatorenal syndrome (HRS).
This review article explores the relationship between low albumin levels and acute kidney injury (AKI).
This meta-analysis pooled data from three large randomised controlled trials to determine whether early goal-directed therapy (EGDT) was an effective intervention for managing septic shock.
This systematic review and meta-analysis looked at the different mortality rates of various intravenous fluids and fluid protocols when used for resuscitation in sepsis.
This Chinese randomised controlled study explores the impact that a goal-directed fluid restriction (GDFR) protocol had on outcomes during anaesthesia for brain surgery.
This review paper examines the role of albumin in chronic liver disease, assessing the evidence for its use in several key clinical areas.
This matched cohort study aimed to determine whether a goal-directed fluid therapy (GDFT) intervention, delivered intraoperatively, would reduce post-operative morbidity in patients undergoing hip revision surgery.
This study explored fluid prescribing practices in intensive care – providing a picture of how fluid resuscitation is being managed internationally.
This multicentre audit reviewed the records of 431 patients who had undergone major elective surgery. The authors sought to determine how well IV fluids were prescribed both intraoperatively and perioperatively when compared with current guidance.
This double-blinded, randomised controlled trial examined whether pre-operative administration of exogenous albumin affected rates of acute kidney injury (AKI).
This article is a review and summary of the current opinion of albumin in fluid management.
This retrospective, observational study used a propensity scoring system to match patients treated with saline with those given a balanced, calcium-free fluid.
A recent PRAC review has recommended suspension of marketing authorisations for HES solutions for infusion across the EU.
Following the European Medicines Agency’s (EMA) suspension of the marketing authorisations of hydroxyethyl starch (HES) solutions across the European Union (EMA, 2018), Roberts et al., have written an open letter addressed to the World Health Organization (WHO) Director General seeking support for the suspension of HES solutions and expanding it to a worldwide ban.
The Coordination Group for Mutual Recognition and Decentralised Procedures (CMDh) endorse the suspension of hydroxyethyl-starch (HES) solutions, due to serious risks of kidney injury and death in certain patient populations.
The hypothesis that hypertonic fluid has a dual physiological role, increasing circulatory volume while administering minimal volumes and muting the pro-inflammatory response to injury and illness, may be appealing, but is it superior to isotonic fluids in practice?
In this post-hoc, subgroup analysis (study 1) and prospective, single-centre nested cohort (study 2) from the SPLIT (0.9% saline vs. PL-148 for ICU fluid therapy) trial, the investigators hypothesised that patients receiving Plasma-Lyte 148 would require fewer blood products and have less post-operative bleeding than those receiving saline.
Acute kidney injury (AKI) affects one-fifth of major surgery patients, increasing the risk of long-term mortality. This review paper discusses recent study data, discussing the best methods for preventing postoperative AKI.
Guidelines to promote the early recovery of patients undergoing major surgery recommend a restrictive intravenous-fluid strategy for abdominal surgery. However, the supporting evidence is limited, and there is concern about impaired organ perfusion.
Cirrhosis of the liver is a leading cause of mortality. For patients with decompensated cirrhosis, long-term weekly human albumin administration can act as an effective disease-modifying treatment.
In 1896 Ernest Starling published his hypothesis for fluid exchange, whereby fluid exchange exists mainly in the capillaries through a process of plasma ultrafiltration across semipermeable membranes (Starling, 1896). But is this 19th century theory something of the past?
Long-term albumin treatment for ascites associated with cirrhosis has been debated in recent years, with mixed results reported for the treatment’s efficacy. In this non-randomised prospective study, Di Pascoli and colleagues question the benefits of long-term albumin in patients with liver cirrhosis and refractory ascites, focussing on survival and emergent hospitalisations. Could this be part of the solution to the ongoing challenge of ascites in cirrhosis?
The choice of fluid administered during cardiac surgery remains a debated topic, often focussed around colloid solutions containing albumin. Conflicting results from numerous studies have left questions over albumin safety and potential to be superior to crystalloids during surgery. Kingeter et al. hoped to achieve clarity on this controversial topic in a retrospective study of cardiac surgery outcomes over a 12-year period.
Patients admitted to intensive care are often haemodynamically unstable with fluid resuscitation therapy regularly used to overcome this. The use of small volume resuscitation with 20% albumin has historically been limited compared to standard fluid resuscitation with 4–5% albumin due to safety concerns, but could those concerns be misplaced? Read more about how the SWIPE trial has provided new insights into the possibilities of using small volume resuscitation within the ICU.